Relationship of baseline PSA and degree of PSA decline to radiographic progression-free survival (rPFS) in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302

被引：0
|
作者：
Ryan, Charles J.
Londhe, Anil
Molina, Arturo
Smith, Matthew R.
De Bono, Johann Sebastian
Mulders, Peter
Rathkopf, Dana E.
Saad, Fred
Logothetis, Christopher
Fizazi, Karim
Scher, Howard I.
Small, Eric Jay
Matheny, Shannon
Kheoh, Thian San
Griffin, Thomas W.
机构：
[1] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[2] Janssen Res & Dev LLC, Raritan, NJ USA
[3] Janssen Res & Dev LLC, Los Angeles, CA USA
[4] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[5] Royal Marsden NHS Fdn Trust, Inst Canc Res, Sutton, Surrey, England
[6] Radboud Univ Nijmegen Med Ctr, Nijmegen, Netherlands
[7] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[8] Univ Montreal, Montreal, PQ, Canada
[9] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[10] Univ Paris 11, Inst Gustave Roussy, Villejuif, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5010
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Subgroup analyses of Japanese patients from the PREVAIL trial of enzalutamide (ENZA) in patients with chemotherapy-naive, metastatic castration-resistant prostate cancer (mCRPC).
    Kimura, Go
    Yonese, Junji
    Fukagai, Takashi
    Kamba, Tomomi
    Nishimura, Kazuo
    Nozawa, Masahiro
    Mansbach, Harry H.
    Phung, De
    Beer, Tomasz M.
    Tombal, Bertrand F.
    Ueda, Takeshi
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [42] Response to androgen signaling (AS)-directed therapy after treatment with abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post hoc analysis of study COU-AA-302
    Smith, Matthew R.
    Matheny, Shannon
    Saad, Fred
    Rathkopf, Dana E.
    Mulders, Peter F. A.
    De Bono, Johann Sebastian
    Small, Eric Jay
    Shore, Neal D.
    Fizazi, Karim
    Kheoh, Thian San
    Li, Jinhui
    Todd, Mary Beth
    Griffin, Thomas W.
    Yu, Margaret K.
    Ryan, Charles J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [43] Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate
    Scott T. Tagawa
    Krishnan Ramaswamy
    Ahong Huang
    Jack Mardekian
    Neil M. Schultz
    Li Wang
    Rickard Sandin
    Stanislav Lechpammer
    Daniel J. George
    Prostate Cancer and Prostatic Diseases, 2021, 24 : 1032 - 1040
  • [44] PSA response to cabazitaxel is associated with improved progression-free survival in metastatic castration-resistant prostate cancer: the non-interventional QoLiTime study
    Hammerer, Peter
    Al-Batran, Salah-Eddin
    Windemuth-Kieselbach, Christine
    Keller, Martin
    Hofheinz, Ralf-Dieter
    WORLD JOURNAL OF UROLOGY, 2018, 36 (03) : 375 - 381
  • [45] PSA response to cabazitaxel is associated with improved progression-free survival in metastatic castration-resistant prostate cancer: the non-interventional QoLiTime study
    Peter Hammerer
    Salah-Eddin Al-Batran
    Christine Windemuth-Kieselbach
    Martin Keller
    Ralf-Dieter Hofheinz
    World Journal of Urology, 2018, 36 : 375 - 381
  • [46] Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302)
    Rathkopf, Dana E.
    Smith, Matthew R.
    de Bono, Johann S.
    Logothetis, Christopher J.
    Shore, Neal D.
    de Souza, Paul
    Fizazi, Karim
    Mulders, Peter F. A.
    Mainwaring, Paul
    Hainsworth, John D.
    Beer, Tomasz M.
    North, Scott
    Fradet, Yves
    Van Poppel, Hendrik
    Carles, Joan
    Flaig, Thomas W.
    Efstathiou, Eleni
    Yu, Evan Y.
    Higano, Celestia S.
    Taplin, Mary-Ellen
    Griffin, Thomas W.
    Todd, Mary B.
    Yu, Margaret K.
    Park, Youn C.
    Kheoh, Thian
    Small, Eric J.
    Scher, Howard I.
    Molina, Arturo
    Ryan, Charles J.
    Saad, Fred
    EUROPEAN UROLOGY, 2014, 66 (05) : 815 - 825
  • [47] Relationship between abiraterone exposure, prostate-specific antigen (PSA) kinetics, and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Xu, Steven
    Ryan, Charles J.
    Stuyckens, Kim
    Smith, Matthew R.
    Saad, Fred
    Griffin, Thomas W.
    Park, Youn Choi
    Yu, Margaret K.
    Vermeulen, An
    Poggesi, Italo
    Nandy, Partha
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [48] The PREVAIL trial of enzalutamide (ENZA) in men with chemotherapy-naive, metastatic castration-resistant prostate cancer (mCRPC): subgroup analysis of Asian patients
    Kim, Choung-soo
    Choi, Young Deuk
    Lee, Sangchul
    Lee, Hyun Moo
    Ueda, Takeshi
    Yonese, Junji
    Fukagai, Takashi
    Mansbach, Harry
    Theeuwes, Ad
    Beer, Tomasz M.
    Tombal, Bertrand
    Kimura, Go
    BJU INTERNATIONAL, 2015, 116 : 14 - 14
  • [49] Correction: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate
    Scott T. Tagawa
    Krishnan Ramaswamy
    Ahong Huang
    Jack Mardekian
    Neil M. Schultz
    Li Wang
    Rickard Sandin
    Stanislav Lechpammer
    Daniel J. George
    Prostate Cancer and Prostatic Diseases, 2022, 25 : 804 - 804
  • [50] Correction to: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate
    Scott T. Tagawa
    Krishnan Ramaswamy
    Ahong Huang
    Jack Mardekian
    Neil M. Schultz
    Li Wang
    Rickard Sandin
    Stanislav Lechpammer
    Daniel J. George
    Prostate Cancer and Prostatic Diseases, 2022, 25 : 800 - 801
12345